Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.
DSM’s XD technology has been developed as a proprietary system to drive yield improvements in mammalian systems. ‘XD’ stands for extreme density, as the process is able to push the cell density within the bioreactor to maximum productivity.